Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Hormone deficiency may be the cause for chronic diarrhoea

A common type of chronic diarrhoea may be caused by a hormone deficiency, according to new research published in the November issue of Clinical Gastroenterology and Hepatology.

3 Nov 2009

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem Inc. announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.

2 Nov 2009

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's automated SQiDworks(TM) Diagnostics Platform and its multiplexed IgXPLEX(TM) rheumatoid arthritis (RA) assay for marketing in the United States.

2 Nov 2009

Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shots

The Centers for Disease Control and Prevention (CDC) have classified all children, 6-months to 24-years, one of the high risk groups for contracting the H1N1 (swine) flu, and recommend this population receive the H1N1 vaccine for immunity against the disease.

30 Oct 2009

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

The La Jolla Institute for Allergy & Immunology, an international leader in immunology research and San Diego's only research institute focused solely on immune-mediated diseases, today will dedicate its new Elam Discovery Wall and Type 1 Diabetes Center, which will focus on research into novel immunological-focused approaches to type 1 diabetes.

30 Oct 2009

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

Today is World Psoriasis Day and the National Psoriasis Foundation is asking all Americans affected by psoriasis and psoriatic arthritis to raise awareness about these diseases by going to www.psoriasis.org/wpd and taking action.

29 Oct 2009

Steroid-induced osteoporosis can now be treated with Teriparatide

A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate.

29 Oct 2009

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

The human body contains billions of microorganisms, and microbial cells found in the human gut are estimated to outnumber human cells by ten-to-one in healthy adults. However, little is known about the ways in which these minute life forms influence health and disease.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Results from the largest prospective controlled ulcerative colitis (UC) trial conducted to date, called the QD dosing investigation for efficacy IN UC maintenance (QDIEM), found that once-daily dosing of Asacol(R) (mesalamine) delayed-release 400 mg tablets at 1.6-2.4 g/day was comparable to twice-daily dosing for the maintenance of remission in patients with UC.

28 Oct 2009

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Elan Corporation, plc and Biogen Idec today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s disease during both induction and maintenance treatment.

28 Oct 2009

Shire receives European approval for FOSRENOL

Shire plc, the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL(R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1.78mmol/L (5.5mg/dL).

28 Oct 2009

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Drawing on years of experience in cancer research and patient care, The University of Texas M. D. Anderson Cancer Center released today the most comprehensive, risk-based screening guidelines publicly available to date for breast, cervical and colorectal cancers.

27 Oct 2009

Detecting the cause of occult gastrointestinal bleeding with the PillCam SB video capsule demonstrated

Given Imaging Ltd. today announced that new data presented at the American College of Gastroenterology (ACG) 2009 Conference show that by visualizing the small bowel with the PillCam® SB video capsule, physicians can detect the cause of occult gastrointestinal bleeding (OGIB) and adapt how they manage and treat these patients.

27 Oct 2009

ACC's initiative for health care reform

As lawmakers debate health care reform, business innovator Lou Weisbach and Clinton White House health care advisor Dr. Richard Boxer are available for interviews to discuss a glaring, missing element of the forthcoming health care legislation: reducing health care costs -- and saving lives -- by preventing and curing disease.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

Findings from a new retrospective cohort study presented at the American College of Gastroenterology's 74th Annual Scientific meeting in San Diego indicate that patients with Inflammatory Bowel Disease (IBD), especially those receiving the thiopurine class of medications to treat IBD, may be at risk for developing non-melanoma skin cancer (NMSC).

27 Oct 2009

Japanese Patent granted for Pharmalink AB's Nefecon

Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China.

26 Oct 2009

Probiotic therapy can be effective for treating intestinal disorders

The probiotic, Bacillus polyfermenticus, can help mice recover from colitis, a new study has found. Mice treated with B. polyfermenticus during the non-inflammatory period of the disease had reduced rectal bleeding, their tissues were less inflamed and they gained more weight than mice that did not receive the treatment.

26 Oct 2009

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Hormone deficiency may be the cause for chronic diarrhoea

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

SQI Diagnostics' SQiDworks automated platform and IgXPLEX RA assay receive FDA marketing clearance

Patients on immunosuppressant medication can receive H1N1 vaccine in the form of shots

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

Raise awareness about psoriasis: National Psoriasis Foundation's call to psoriasis affected Americans

Steroid-induced osteoporosis can now be treated with Teriparatide

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Treatment with TYSABRI reduces the rate of hospitalization in Crohn’s patients

Shire receives European approval for FOSRENOL

Comprehensive, risk-based screening guidelines for breast, cervical and colorectal cancers

Detecting the cause of occult gastrointestinal bleeding with the PillCam SB video capsule demonstrated

ACC's initiative for health care reform

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Patients with Inflammatory Bowel Disease may be at risk for developing non-melanoma skin cancer

Japanese Patent granted for Pharmalink AB's Nefecon

Probiotic therapy can be effective for treating intestinal disorders

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in